Notably, a recent clinical study reported addition of the BCL-2 specific BH3-mimetic venetoclax to a nelarabine-containing chemotherapy regimen in T-ALL/LBL with promising results [107]. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.